Skip to search formSkip to main contentSkip to account menu

XL999

Known as: SSKI XL999, XL-999, FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999 
A small molecule inhibitor of numerous tyrosine kinases (TKs) including fibroblast growth factor receptor (FGFR), vascular endothelial growth factor… 
National Institutes of Health

Related topics

Related topics

3 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Broader (1)

Organic Chemicals

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Integrated report of the phase 2 experience with XL999 administered IV to patients (pts) with NSCLC, renal cell CA (RCC), metastatic colorectal CA (CRC), recurrent ovarian CA, acute myelogenous…
3591 Background: XL999 is a potent spectrum-selective inhibitor of tyrosine kinases including VEGFR2/KDR, FGFR1/3, PDGFR-β, FLT3… 
2007
2007
Evaluation of XL999, a Potent Inhibitor of FGFR3, for the Potential Treatment of t(4;14) Positive Multiple Myeloma.
Recent advances in our understanding of the molecular pathogenesis of Multiple Myeloma (MM) have provided novel therapeutic… 
2007
2007
Gateways to clinical trials.
Agomelatine, AGRO-100, AIDSVAX gp120 B/E, alfimeprase, aliskiren fumarate, ALVAC vCP1452, alvocidib hydrochloride, ambrisentan… 
2006
2006
83 POSTER A phase I study examining weekly weight based or fixed dosing and pharmacokinetics (PK) of a novel spectrum kinase inhibitor, XL999, in patients (pts) with advanced solid malignancies (ASM)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)